RNF182 Inhibitors
Chemical inhibitors of the proteasome can disrupt the function of proteins that rely on this complex for their regulatory roles in cellular protein turnover. One such protein affected is RNF182, which is understood to serve as an E3 ubiquitin-protein ligase, tagging proteins with ubiquitin to signal for their degradation via the proteasome. When proteasome inhibitors such as MG132, Lactacystin, and Epoxomicin are introduced, they bind to the proteasome in a manner that prevents it from breaking down ubiquitinated proteins. MG132 achieves this by reversibly inhibiting the proteasome, while Lactacystin and Epoxomicin form irreversible bonds with the proteasome's catalytic sites. This inhibition results in the accumulation of ubiquitinated proteins within the cell, which includes those tagged by RNF182, effectively stalling the protein's role in the regulated degradation process.
Other inhibitors, like Velcade and Carfilzomib, target the 26S and 20S proteasome, respectively. Velcade, a dipeptide boronic acid analog, and Carfilzomib, a tetrapeptide epoxyketone, both bind to proteasome subunits, thus halting the degradation process. Similarly, Oprozomib, Ixazomib, Marizomib, Delanzomib, and MLN2238 (Ixazomib citrate) also inhibit the proteasome, with Oprozomib and Ixazomib being notable for their capacity to be administered orally. These inhibitors, by holding up the proteasome's function, cause an increase in the presence of proteins that would normally be marked and degraded by RNF182. Pyrazolanthrone acts upstream by affecting signaling pathways that may regulate the activity or expression of RNF182, thus indirectly influencing its function. Collectively, these inhibitors exert a multi-faceted blockade on the degradation pathway critical for RNF182's role in cellular homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that can inhibit the proteasomal degradation pathway. By inhibiting this pathway, it can lead to the accumulation of ubiquitinated proteins, potentially including RNF182, which is an E3 ubiquitin-protein ligase. The accumulation of ubiquitinated proteins can saturate the proteasome, leading to a reduction in the proteasomal degradation of RNF182 substrates. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is another proteasome inhibitor that irreversibly binds to and inhibits the 20S proteasome. Similar to MG132, by inhibiting the proteasome, Lactacystin can prevent the degradation of proteins that are tagged for degradation by RNF182, thereby hindering RNF182's ability to regulate protein turnover. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor that covalently binds to the active site of the proteasome. This binding inhibits the degradation of polyubiquitinated proteins, which could include those ubiquitinated by RNF182. The resulting accumulation of polyubiquitinated proteins can indirectly inhibit RNF182's functional role in protein degradation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Velcade is a dipeptide boronic acid analog that inhibits the 26S proteasome. By inhibiting the proteasome, Velcade can lead to the buildup of proteins marked for degradation by RNF182, thus inhibiting the protein's functional role in proteasomal degradation pathways. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $40.00 | ||
Carfilzomib is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It irreversibly binds to the N-terminal threonine-containing active sites of the 20S proteasome, the same pathway used by RNF182 to target proteins for degradation, effectively inhibiting the protein's functional role. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib is an oral proteasome inhibitor that can inhibit the chymotrypsin-like activity of the proteasome. In doing so, it hampers the degradation of ubiquitinated proteins, thereby indirectly hindering the protein degradation function of RNF182 by causing a backlog of substrates. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib is a small-molecule proteasome inhibitor. By inhibiting the proteasome, Ixazomib can lead to the accumulation of proteins targeted for degradation by RNF182, thus interfering with the protein's role in the ubiquitin-proteasome system. | ||||||
UCH-L1 Inhibitor Inhibitor | 668467-91-2 | sc-356182 | 10 mg | $200.00 | 1 | |
Delanzomib is a boronic acid-based proteasome inhibitor that targets the 20S proteasome. By impeding proteasomal activity, Delanzomib can cause the accumulation of protein substrates of RNF182, thereby indirectly inhibiting the enzymatic activity of RNF182. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
Pyrazolanthrone is a JNK inhibitor that can indirectly inhibit RNF182 by interfering with the JNK signaling pathway, which could be involved in the regulation of RNF182 activity or expression. By blocking JNK, it may reduceIt seems like there was a misunderstanding. Please provide me with the context or question related to these substances, and I'll be happy to provide a tailored response. | ||||||